Previous Close | 116.99 |
Open | 114.98 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's Range | 113.82 - 115.50 |
52 Week Range | 92.19 - 120.92 |
Volume | |
Avg. Volume | 1,251,141 |
Market Cap | 235.443B |
Beta (5Y Monthly) | 0.50 |
PE Ratio (TTM) | 23.92 |
EPS (TTM) | 4.82 |
Earnings Date | Oct 29, 2024 |
Forward Dividend & Yield | 3.78 (3.23%) |
Ex-Dividend Date | Mar 07, 2024 |
1y Target Est | 115.96 |
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Shares of Novartis (SIX:NOVN) were down on Wednesday following a downgrade by BofA Securities, which downgraded the Swiss pharmaceutical giant to "neutral" from "buy." At 4:01 am (0801 GMT), Novartis was trading 2.4% lower at CHF 96.48. BofA also lowered its price target for Novartis to CHF110 from CHF120, reflecting growing apprehensions about the company's near-term potential for outperformance.